Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 501575104 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
14.3% |
5/6/2026
Event 3/31/2026
|
||
| FMR LLC | 14.3% | |||
| Abigail P. Johnson | 14.3% | |||
|
Baker Bros. Advisors LP
13D/A
|
10.9% |
12/11/2025
Event 12/9/2025
|
||
| Baker Bros. Advisors LP | 10.9% | |||
| Baker Bros. Advisors (GP) LLC | 10.9% | |||
| Julian C. Baker | 10.9% | |||
| Felix J. Baker | 10.9% | |||
| Price T Rowe Associates Inc /MD/ 13G/A | 10.7% |
9/8/2026
Event 8/31/2026
|
||
| T. Rowe Price Investment Management, Inc. 13G | 6.7% |
5/15/2026
Event 3/31/2026
|
||
|
Biotechnology Value Fund L P
13D/A
|
6.3% |
6/26/2026
Event 6/26/2026
|
||
| Biotechnology Value Fund L P | 3.3% | |||
| BVF I GP LLC | 3.3% | |||
| Biotechnology Value Fund II LP | 2.6% | |||
| BVF II GP LLC | 2.6% | |||
| Biotechnology Value Trading Fund OS LP | 0.4% | |||
| BVF Partners OS Ltd. | 0.4% | |||
| BVF GP Holdings LLC | 5.8% | |||
| BVF Partners L P/IL | 6.3% | |||
| BVF Inc/IL | 6.3% | |||
| Lampert Mark N | 6.3% | |||
| Hrustanovic Gorjan | 0.1% | |||
| BlackRock, Inc. 13G/A | 5.4% |
7/17/2025
Event 6/30/2025
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Wellington Management Group LLP
13G/A
|
4.8% |
5/15/2026
Event 3/31/2026
|
||
| Wellington Management Group LLP | 4.8% | |||
| Wellington Group Holdings LLP | 4.8% | |||
| Wellington Investment Advisors Holdings LLP | 4.8% | |||
|
Atlas Venture Fund X, L.P.
13G/A
|
2.9% |
8/13/2026
Event 6/30/2026
|
||
| Atlas Venture Fund X, L.P. | 2.9% | |||
| Atlas Venture Associates X, L.P. | 2.9% | |||
| Atlas Venture Associates X, LLC | 2.9% | |||
| Atlas Venture Opportunity Fund I, L.P. | 0.6% | |||
| Atlas Venture Associates Opportunity I, L.P. | 0.6% | |||
| Atlas Venture Associates Opportunity I, LLC | 0.6% | |||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 17 | 21.7 k | $2.15 M |
| 2026 Q2 | 294 | 103 M | $11.1 B |
| 2026 Q1 | 265 | 96.3 M | $8.01 B |
| 2025 Q4 | 270 | 90.0 M | $7.00 B |
| 2025 Q3 | 220 | 81.1 M | $4.59 B |
| 2025 Q2 | 222 | 79.0 M | $3.45 B |
| 2025 Q1 | 188 | 72.9 M | $2.00 B |
| 2024 Q4 | 190 | 71.7 M | $2.88 B |
| 2024 Q3 | 185 | 69.2 M | $3.27 B |
| 2024 Q2 | 163 | 68.2 M | $2.03 B |
| 2024 Q1 | 173 | 68.8 M | $2.77 B |
| 2023 Q4 | 145 | 62.1 M | $1.58 B |
| 2023 Q3 | 126 | 57.4 M | $797 M |
| 2023 Q2 | 134 | 58.4 M | $1.34 B |
| 2023 Q1 | 136 | 56.9 M | $1.68 B |
| 2022 Q4 | 135 | 59.1 M | $1.47 B |
| 2022 Q3 | 136 | 52.9 M | $1.15 B |
| 2022 Q2 | 104 | 49.4 M | $974 M |
| 2022 Q1 | 136 | 45.8 M | $1.94 B |
| 2021 Q4 | 139 | 43.7 M | $2.77 B |
| 2021 Q3 | 121 | 34.6 M | $2.04 B |
| 2021 Q2 | 115 | 26.5 M | $1.29 B |
| 2021 Q1 | 100 | 22.8 M | $887 M |
| 2020 Q4 | 77 | 20.3 M | $1.25 B |
| 2020 Q3 | 53 | 16.8 M | $543 M |